These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl-3-yl ester (URB597): effects on anandamide and oleoylethanolamide deactivation. Fegley D, Gaetani S, Duranti A, Tontini A, Mor M, Tarzia G, Piomelli D. J Pharmacol Exp Ther; 2005 Apr 26; 313(1):352-8. PubMed ID: 15579492 [Abstract] [Full Text] [Related]
15. Temporal changes in N-acylethanolamine content and metabolism throughout the peri-adolescent period. Lee TT, Hill MN, Hillard CJ, Gorzalka BB. Synapse; 2013 Jan 26; 67(1):4-10. PubMed ID: 22987804 [Abstract] [Full Text] [Related]
16. Evaluation of fatty acid amides in the carrageenan-induced paw edema model. Wise LE, Cannavacciulo R, Cravatt BF, Martin BF, Lichtman AH. Neuropharmacology; 2008 Jan 26; 54(1):181-8. PubMed ID: 17675189 [Abstract] [Full Text] [Related]
18. Manipulation of Arabidopsis fatty acid amide hydrolase expression modifies plant growth and sensitivity to N-acylethanolamines. Wang YS, Shrestha R, Kilaru A, Wiant W, Venables BJ, Chapman KD, Blancaflor EB. Proc Natl Acad Sci U S A; 2006 Aug 08; 103(32):12197-202. PubMed ID: 16880402 [Abstract] [Full Text] [Related]
19. Comparative analysis of fatty acid amide hydrolase and cb(1) cannabinoid receptor expression in the mouse brain: evidence of a widespread role for fatty acid amide hydrolase in regulation of endocannabinoid signaling. Egertová M, Cravatt BF, Elphick MR. Neuroscience; 2003 Aug 08; 119(2):481-96. PubMed ID: 12770562 [Abstract] [Full Text] [Related]